Tim Smith

These data, presented at RAD 2024, highlight the potential benefits of upadacitinib for adults and adolescents observed in the Measure Up 1 and Measure Up 2 studies.

This approval by FDA officials allows patients an alternative option to pre-filled syringe, which had been the only choice for those with eczema prescribed tralokinumab.

Sidbury covered the similarities and differences between the new guideline updates by the AAD on atopic dermatitis as well as differences with other organizations’ guidelines.

In new late-breaking data, alopecia patients’ real-world incidence of atopic dermatitis was highlighted by investigators.

These data presented at RAD 2024 highlight the differences among eczema patient preferences in terms of administration modes, risk levels, and more.

This late-breaking data featured at RAD 2024 highlights several improvements in patient reported outcomes observed among atopic dermatitis patients, including itch relief.

This interview at RAD 2024 featured a discussion by Bissonnette of recent data related to 4 topical drugs for patients with atopic dermatitis.

In his RAD 2024 talk, Bissonnette presented recent data on 4 topical drugs for atopic dermatitis, including crisaborole and ruxolitinib.

Jonathan Silverberg, MD, PhD, MPH, discusses how the results of the LEVEL UP trial impact treatment decisions for patients with moderate-to-severe atopic dermatitis.

Treating eczema twice-daily with ruxolitinib cream, 1.5% led to positive results for children in the age range of 2 to 11 years.

In this open-label extension trial presented at RAD 2024, the long-term safety and efficacy results of roflumilast cream in adults and children with eczema was highlighted.

Rosmarin discussed several treatments in development covered in his RAD 2024 presentation for the treatment of patients with eczema.

In this interview, Chovatiya spoke about his second RAD 2024 talk regarding achieving remission with currently available eczema treatments.

This RAD 2024 interview featured a discussion of currently FDA-approved atopic dermatitis therapies and their comparisons.

This segment of Paller’s RAD 2024 interview covers tips for treating children with biologics as well as unmet needs of eczema patients and upcoming treatments.

In her presentation at RAD 2024, Singh highlighted ways to manage the atopic comorbidities linked to eczema in children.

The global, real-world TRACE study was designed to improve the understanding of tralokinumab’s safety, efficacy, and clinical utilization in daily practice for eczema.

In her RAD conference interview, Paller describes several treatments featured in her talk on the subject of pediatric eczema.

This interview with Silverberg featured a discussion of new data on systemic therapies for various dermatologic conditions.

In an interview at RAD 2024, Silverberg discusses ways to help patients navigate such comorbidities associated with eczema.

These data indicate the benefits of implementing individual protective measures in winter by patients with COPD.

These data suggest that those with psoriasis maintain an innate psychological vulnerability, indicating the necessity of addressing mental well-being in the disease’s management.

The investigators looked at patients whose severity improved based on either the Physician Global Assessment or the modified Localized Scleroderma Severity Index.

This analysis looked at the efficacy and safety of 200-mg of orally-administered abrocitinib at a rate of once daily, highlighting the drug’s use among patients with CPUO or PN.

These data suggest an association between dietary sodium intake and severity of eczema among patients.

The VIO Skin Platform by Enspectra Health was designed to assess lesions indicating either basal cell carcinoma or squamous cell carcinoma.

This review of May 2024 covered several notable topics in the pulmonary health field, including research into vaping, lung abnormalities, and treatment of COPD.

The month of May 2024 featured several notable studies in the field of dermatology, concerning topics such as a potential eczema flare vaccine, mobile versus in-person health, and skin cancer risk.

These multicenter, retrospective data highlight the use of guselkumab after discontinuing ustekinumab treatment up to 156 weeks of use.

These new, phase 3 data from Novartis suggest positive results from treatment with oral remibrutinib for patients with chronic spontaneous urticaria.